SAN DIEGO, November 17, 2021 – Lynx Biosciences, Inc. (LynxBio®), a biotechnology company generating unparalleled biological insights through integrated multi-omics, today announced the appointment of Sylvaine Cases, Ph.D., as the company's first Chief Business Officer (CBO). Dr. Cases joins LynxBio from Johnson & Johnson, where she was Vice President of Oncology Strategic Partnering. She brings 20 years of combined R&D and business development expertise across a wide range of therapeutic modalities. At LynxBio, Dr. Cases will lead the commercial strategy and continued growth of LynxBio's oncology partnering program, which currently spans a diverse portfolio of immuno-oncology therapeutics. LynxBio’s platform combines patient-derived disease models with high-content imaging and orthogonal omics readouts, providing integrative, multi-omic disease signatures to accelerate oncology drug development and identify composite biomarkers predictive of therapeutic response.
"Sylvaine is a proven life sciences executive with an outstanding track record of sourcing and executing major platform deals in the immuno-oncology space," says Chorom Pak, Ph.D., Founder and CEO of LynxBio. "Her ability to bridge science and business, coupled with her partnering experience in hematological indications, will be instrumental as we continue to execute on our strategy of partnering our multi-omics platform and enter LynxBio's next phase. We are excited to have Sylvaine join our team and are looking forward to her leadership in expanding our programs with current and future partners."
“LynxBio has built a novel multi-omics platform exquisitely suited for characterizing liquid tumors to provide differentiated biological and therapeutic data in complex diseases," said Dr. Cases. "I have followed the growth of the company and continue to be impressed with the team's energy, dedication, and deep science. I am thrilled to be joining the LynxBio team at this important moment for the company and look forward to helping advance ongoing collaborations on numerous drug programs as well as internal program development.”
In the past ten years, Dr. Cases has held leadership positions of increased responsibilities in external research and partnering, first at Sanofi and most recently at Johnson & Johnson, where she helped develop an industry-leading portfolio in oncology through negotiated collaborations, partnerships, and investments. Her previous roles in biotech focused on leading R&D teams and included Head of Pharmacology at Arete Therapeutics and Senior Group Leader at Cytokinetics, where she headed programs in cancer pharmacology and translational oncology. Prior to moving to the private sector, she held an academic appointment at the Gladstone Institutes at UCSF, where she focused her research on metabolism and cancer with an emphasis on the tumor microenvironment.
About Lynx Biosciences, Inc.
Lynx Biosciences, Inc. (LynxBio®) is a biotechnology company generating unparalleled biological insights by combining patient-derived disease models with high-content imaging and multi-omic readouts. By functionally characterizing tumors in the context of autologous immune components, LynxBio leverages its proprietary platform to provide integrative, multi-omic disease signatures, identify composite biomarkers predictive of therapeutic response, and discover immuno-oncology targets with a higher probability of translational success.
LynxBio® is a registered trademark of Lynx Biosciences, Inc.
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., email@example.com, +1.858.344.8091
Company: Benjamin Titz, Ph.D., VP of Corporate Development, firstname.lastname@example.org, +1.619.880.3088